These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

411 related items for PubMed ID: 10783014

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Safety of Tdap-IPV given one month after Td-IPV booster in healthy young adults: a placebo-controlled trial.
    Beytout J, Launay O, Guiso N, Fiquet A, Baudin M, Richard P, Baptiste C, Soubeyrand B.
    Hum Vaccin; 2009 May; 5(5):315-21. PubMed ID: 19011374
    [Abstract] [Full Text] [Related]

  • 6. Repeated administration of a reduced-antigen-content diphtheria-tetanus-acellular pertussis and poliomyelitis vaccine (dTpa-IPV; Boostrix™ IPV).
    Knuf M, Vetter V, Celzo F, Ramakrishnan G, Van Der Meeren O, Jacquet JM.
    Hum Vaccin; 2010 Jul; 6(7):554-61. PubMed ID: 20448468
    [Abstract] [Full Text] [Related]

  • 7. Immunogenicity and reactogenicity of a decennial booster dose of a combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and inactivated poliovirus booster vaccine (dTpa-IPV) in healthy adults.
    Kovac M, Rathi N, Kuriyakose S, Hardt K, Schwarz TF.
    Vaccine; 2015 May 21; 33(22):2594-601. PubMed ID: 25882172
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Comparative reactogenicity and immunogenicity of booster doses of diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine and diphtheria-tetanus-inactivated poliovirus vaccine in preadolescents.
    Bégué PC, Grimprel EM, Giovannangeli MD, Abitbol VI.
    Pediatr Infect Dis J; 1998 Sep 21; 17(9):804-9. PubMed ID: 9779766
    [Abstract] [Full Text] [Related]

  • 12. Immunogenicity and safety of one dose of diphtheria, tetanus, acellular pertussis and poliomyelitis vaccine (Repevax®) followed by two doses of diphtheria, tetanus and poliomyelitis vaccine (Revaxis®) in adults aged ≥ 40 years not receiving a diphtheria- and tetanus-containing vaccination in the last 20 years.
    Dominicus R, Galtier F, Richard P, Baudin M.
    Vaccine; 2014 Jun 30; 32(31):3942-9. PubMed ID: 24852717
    [Abstract] [Full Text] [Related]

  • 13. Randomized Controlled Trial of the Safety and Immunogenicity of Revaccination With Tetanus-Diphtheria-Acellular Pertussis Vaccine (Tdap) in Adults 10 Years After a Previous Dose.
    Halperin SA, Donovan C, Marshall GS, Pool V, Decker MD, Johnson DR, Greenberg DP, Tdap Booster Investigators.
    J Pediatric Infect Dis Soc; 2019 May 11; 8(2):105-114. PubMed ID: 29438562
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Safety and immunogenicity of two inactivated poliovirus vaccines in combination with an acellular pertussis vaccine and diphtheria and tetanus toxoids in seventeen- to nineteen-month-old infants.
    Halperin SA, Davies HD, Barreto L, Guasparini R, Meekison W, Humphreys G, Eastwood BJ.
    J Pediatr; 1997 Apr 11; 130(4):525-31. PubMed ID: 9108847
    [Abstract] [Full Text] [Related]

  • 16. Safety and immunogenicity of Haemophilus influenzae-tetanus toxoid conjugate vaccine given separately or in combination with a three-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine for the first four doses.
    Halperin SA, King J, Law B, Mills E, Willems P.
    Clin Infect Dis; 1999 May 11; 28(5):995-1001. PubMed ID: 10452624
    [Abstract] [Full Text] [Related]

  • 17. Immunogenicity, safety, and antibody persistence at 3, 5, and 10 years postvaccination in adolescents randomized to booster immunization with a combined tetanus, diphtheria, 5-component acellular pertussis, and inactivated poliomyelitis vaccine administered with a hepatitis B virus vaccine concurrently or 1 month apart.
    Embree J, Law B, Voloshen T, Tomovici A.
    Clin Vaccine Immunol; 2015 Mar 11; 22(3):282-90. PubMed ID: 25540274
    [Abstract] [Full Text] [Related]

  • 18. [The immunological basis of the administration of DTP-polio vaccine].
    Cohen H.
    Verh K Acad Geneeskd Belg; 2000 Mar 11; 62(4):245-67. PubMed ID: 11004905
    [Abstract] [Full Text] [Related]

  • 19. Safety and immunogenicity of a toddler dose following an infant series of a hexavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b, hepatitis B vaccine administered concurrently or at separate visits with a heptavalent pneumococcal conjugate vaccine.
    Halperin SA, Tapiéro B, Dionne M, Meekison W, Diaz-Mitoma F, Zickler P, Rubin E, Embree J, Bhuyan P, Lee A, Li M, Tomovici A.
    Pediatr Infect Dis J; 2014 Jan 11; 33(1):73-80. PubMed ID: 24346596
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.